Business Wire

IL-SHIPPEO

2.4.2024 11:00:27 CEST | Business Wire | Press release

Share
Shippeo Named a Leader in the 2024 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms, Announces Record Growth in North America and APAC

Shippeo has been named a Leader in the 2024 Gartner® Magic Quadrant for Real-Time Transportation Visibility Platforms. The global multimodal shipment visibility platform was also recently named a Customers’ Choice by Gartner® in the October 2023 Gartner Peer Insights™ “Voice of the Customer”: Real-Time Transportation Visibility Platforms report, scoring the highest customer recommendation willingness rate of all providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402784237/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Shippeo)

“We are delighted to be recognized as a Leader in this latest Gartner research,” says Shippeo CEO & co-founder, Pierre Khoury. “We are also deeply thankful for the support of our wonderful customers and ecosystem partners, and incredibly proud of our talented teams. As the real-time transportation visibility (RTTV) market continues to mature in North America, Europe, and increasingly across APAC, companies are realizing the significant value visibility brings. From increasing customer NPS with more premium delivery experiences, to reducing operating costs, optimizing processes and cash flow, and monitoring and reducing carbon emissions, our platform is being recognized as an important enabler of next-generation supply chains.”

Strong growth and market momentum in North America, Asia Pacific and Europe

Over the past two years, the company’s customer base tripled. In 2023, the North American revenue grew 153% year over year, with 25% of all new revenue generated having come from companies in this region switching to Shippeo from another provider. Notable new North American customers include Amazon, Barilla, and Palermo Villa, Inc. (dba Palermo’s Pizza). The company also significantly grew its customer base in Asia Pacific, welcoming some of the region’s most recognizable brands, including Yamaha Motor. Notable customers joining in other parts of the world include Arlanxeo, Birra Peroni, DP World, Evonik, Fujifilm and Hartmann Group.

“Our approach to visibility with a greater focus on data quality and customer support has resonated extremely well with the RTTV market in North America,” says Lucien Besse, COO & co-founder at Shippeo. “Since 2020, our partnership with e2open has blossomed into a powerhouse collaboration. Through close cooperation and a shared commitment to excellence, we've achieved remarkable success together, in North America and abroad. This enduring partnership underscores our collective ability to innovate and thrive in today's dynamic landscape.”

Global multimodal visibility network

With established regional head offices in Chicago for the Americas, Singapore for APAC, and Paris for Europe, Shippeo’s network now tracks more than 50 million shipments a year across all modes, in more than 130 countries on six continents, with a 258,000-strong carrier network. Their ocean visibility network covers 99% of the world’s containerships thanks to integrations with major shipping lines. The company’s partner network has also enjoyed continued momentum, now comprising over 1000 system integrations with TMS, WMS, ERPs and telematics devices, representing a 30% increase since the start of 2022. Key strategic partners include e2open, SAP, Infor, Tesisquare, Alpega, Oracle, Siemens, Google, Snowflake, Microsoft, and BlueYonder.

The most recommended provider for three years running

Shippeo has had the highest recommendation rate of all providers on Gartner Peer Insights for over three years. In October 2023, the company was positioned in the Customers’ Choice Quadrant, having scored a 96% recommendation rate, the highest of all providers (based on 116 reviews as of August 2023).

www.shippeo.com/press-releases/shippeo-named-a-leader-in-the-2024-gartner-magic-quadrant-for-real-time-transportation-visibility-platforms

Disclaimer:
GARTNER is a registered trademark and service mark and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
G
artner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2024” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 26 March 2024.

Gartner, “Voice of the Customer for Real-Time Transportation Visibility Platforms”, by Peer Contributors, 31 October 2023.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular Purpose.

Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402784237/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye